April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Correlation of Qualitative and Quantitative OCT With Visual Acuity Outcomes in Treatment-Naïve Patients in the SAILOR 1 Study
Author Affiliations & Notes
  • D. M. Brown
    Vitreoretinal Consultants, Houston, Texas
    The Methodist Hospital, Houston, Texas
  • SAILOR Study
    Vitreoretinal Consultants, Houston, Texas
  • S. Francom
    Genentech, Inc., South San Francisco, California
  • Footnotes
    Commercial Relationships  D.M. Brown, Alcon, Allergan, CoMentis, Genentech, Jerini, NeoVista, Neurotech, Novartis, Othera, Oxigene, Pfizer, Regeneron, F; Alcon, Allergan, Carl Zeiss Meditec, Genentech, Heidelberg Engineering, NeoVista, Novartis, Regeneron, Steba, C; S. Francom, Genentech, E.
  • Footnotes
    Support  This study was supported by Genentech.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5246. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. M. Brown, SAILOR Study, S. Francom; Correlation of Qualitative and Quantitative OCT With Visual Acuity Outcomes in Treatment-Naïve Patients in the SAILOR 1 Study. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5246.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To assess optical coherence tomography (OCT) findings and correlation with visual acuity (VA) in treatment-naïve patients (pts) in Cohort 1 of SAILOR (phase 3b, ranibizumab in neovascular AMD).

Methods: : Pts received 0.3 or 0.5 mg ranibizumab (3 monthly doses and PRN thereafter). Central foveal thickness (CFT) was determined by manual caliper measurements from the fast macular thickness map at a central reading center. A subset of 54 treatment-naïve pts with 6 high-resolution macular thickness map images was chosen for a qualitative OCT analysis (>3800 scans). Pts were graded by a single masked reader and divided into 3 groups (no fluid: pts with resolution of all fluid; recurrent fluid: pts who were initially dry, then treated whenever there was OCT evidence of fluid; persistent fluid: pts whose eye never dried or who had fluid on OCT but were not treated because the OCT change did not meet the retreatment criterion). An outcome measure of interest was mean VA change after 12 months’ treatment.

Results: : In all treatment-naïve pts at 12 months, the mean decrease (± SEM) in CFT was 72 ± 6 and 92 ± 6 µm for the 0.3 and 0.5 mg groups, respectively; the correlation coefficients between changes from baseline in VA and CFT (12 months) were modest (–0.21 and –0.18 for the 0.3 and 0.5 mg groups, respectively). A subset of 54 patients with baseline characteristics similar to those of the overall treatment-naïve group of Cohort 1 included 7 pts with no fluid, 9 with recurrent fluid, and 38 with persistent fluid. At 12 months, the mean change (± SEM) in VA (letter score) from baseline was 7.4 ± 2.8, –0.33 ± 5.6, and 2.0 ± 2.4 for these groups, respectively. Progressive foveal atrophy was demonstrated in pts who had multiple episodes of fluid recurrence.

Conclusions: : Quantitative CFT improved, but correlation with VA changes was modest. Qualitative OCT analysis demonstrated that VA outcomes are better overall when the retina is kept dry and that the presence of fluid (even below the retreatment criterion level) may compromise VA. Progressive foveal atrophy observed after multiple episodes of fluid recurrence may be potentially responsible for the loss of VA gains over time.

Clinical Trial: : www.clinicaltrials.gov NCT00251459

Keywords: age-related macular degeneration • vascular endothelial growth factor 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.